Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Pharming Group N.V. before investing.

In this article, we go over a few key elements for understanding Pharming Group N.V.’s stock price such as:

• Pharming Group N.V.’s current stock price and volume
• Why Pharming Group N.V.’s stock price changed recently
• Upgrades and downgrades for PHAR from analysts
• PHAR’s stock price momentum as measured by its relative strength

About Pharming Group N.V. (PHAR)

Before we jump into Pharming Group N.V.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Want to learn more about Pharming Group N.V.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Pharming Group N.V..

Pharming Group N.V.’s Stock Price as of Market Close

As of August 21, 2026, 4:00 PM, CST, Pharming Group N.V.’s stock price was $11.850.

Pharming Group N.V. is up 1.46% from its previous closing price of $11.680.

During the last market session, Pharming Group N.V.’s stock traded between $11.730 and $11.970. Currently, there are approximately 666.05 million shares outstanding for Pharming Group N.V..

Pharming Group N.V.’s price-earnings (P/E) ratio is currently at 911.5, which is high compared to the Biotechnology industry median of 19.6. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Pharming Group N.V. Stock Price History

Pharming Group N.V.’s (PHAR) price is currently up 17.56% so far this month.

During the month of August, Pharming Group N.V.’s stock price has reached a high of $13.320 and a low of $9.810.

Over the last year, Pharming Group N.V. has hit prices as high as $21.340 and as low as $9.620. Year to date, Pharming Group N.V.’s stock is down 32.94%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Pharming Group N.V. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of August 21, 2026, there were 0 analysts who downgraded Pharming Group N.V.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Pharming Group N.V.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Pharming Group N.V.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Pharming Group N.V.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Pharming Group N.V. (PHAR) by visiting AAII Stock Evaluator.

Relative Price Strength of Pharming Group N.V.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of August 21, 2026, Pharming Group N.V. has a weighted four-quarter relative price strength of -4.99%, which translates to a Momentum Score of 33 and is considered to be Weak.

Want to learn more about how Pharming Group N.V. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Pharming Group N.V. Stock Price: Bottom Line

As of August 21, 2026, Pharming Group N.V.’s stock price is $11.850, which is up 1.46% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Pharming Group N.V. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.